Prostate-Specific Antigen (PSA) Rate of Decline Post External Beam Radiotherapy Predicts Prostate Cancer Death — ASN Events
  1. Schedule
  2. Epidemiology
  3. Posters - Epidemiology
  4. Prostate-Specific Antigen (PSA) Rate of Decline Post External Beam Radiotherapy Predicts Prostate Cancer Death

Prostate-Specific Antigen (PSA) Rate of Decline Post External Beam Radiotherapy Predicts Prostate Cancer Death (#260)

Zumin Shi 1 , Carole B Pinnock 2 3 4 5 , Stephen Kinsey-Trotman 4 , Martin Borg 1 2 6 7 8 , Kim L Moretti 2 4 5 9 , Scoot Walsh 2 3 , Tina Kopsaftis 2 3
  1. University of Adelaide, Adelaide, SA, Australia
  2. SA Prostate Cancer Clinical Outcomes Collaborative, Adelaide, SA, Australia
  3. Urology Unit, Repatriation General Hospital, Adelaide, SA, Australia
  4. School of Medicine, Flinders University, Adelaide, SA, Australia
  5. Discipline of Surgery, University of Adelaide, Adelaide, SA, Australia
  6. Department of Radiation Oncology, Royal Adelaide Hospital, Adelaide, SA, Australia
  7. Division of Health Sciences, University of South Australia, Adelaide, SA, Australia
  8. Adelaide Radiotherapy Centre, Adelaide, SA, Australia
  9. Urology Department, Queen Elizabeth Hospital, Adelaide, SA, Australia

Background and Purpose: To assess the association between PSA velocity (PSAV) in the first 24 months after external beam radiotherapy (EBRT) and prostate cancer-specific mortality (PCSM) and all cause mortality.
Materials and methods: All eligible patients in the South Australian (SA) Prostate Cancer Clinical Outcomes registry were followed. 848 patients treated by definitive EBRT with more than one PSA recorded in the two years post-treatment were included. We calculated PSAV by linear regression.
Results: The mean number of PSA measurements in the 2 year period was 4.4 (SD1.9). The median PSAV across quartiles (Q1-Q4) were -4.17, -1.29, -0.38 and 0.20 ng/ml/yr. In multivariable analysis, a U-shaped relationship was seen between PSAV and PCSM with Q1-Q4 hazard ratios (HR) being 3.82 (1.46-10.00), 3.07(1.10-8.58), 1, 5.15(1.99-13.30) respectively. HR for all cause mortality in a similar model were 1.79(1.07-2.98), 1.55(0.93-2.59), 1.00 and 1.74(1.04-2.90) for Q1 to Q4 respectively. A Rapid PSA decline in the first year was a strong predictor of PCSM. However, in the second year PSA increase was positively associated with PCSM.
Conclusion: A rapid decline in PSA in the first year following EBRT is positively associated with PCSM. This may be a useful early indicator of need for additional therapies.